Genextra Group, Congenia s.r.l., Milan, Italy.
ChemMedChem. 2010 Aug 2;5(8):1359-72. doi: 10.1002/cmdc.201000166.
A series of amidopropenyl hydroxamic acid derivatives were prepared as novel inhibitors of human histone deacetylases (HDACs). Several compounds showed potency at <100 nM in the HDAC inhibition assays, sub-micromolar IC(50) values in tests against three tumor cell lines, and remarkable stability in human and mouse microsomes was observed. Three representative compounds were selected for further characterization and submitted to a selectivity profile against a series of class I and class II HDACs as well as to preliminary in vivo pharmacokinetic (PK) experiments. Despite their high microsomal stability, the compounds showed medium-to-high clearance rates in in vivo PK studies as well as in rat and human hepatocytes, indicating that a major metabolic pathway is catalyzed by non-microsomal enzymes.
一系列丙烯基羟肟酸衍生物被制备为新型人组蛋白去乙酰化酶(HDAC)抑制剂。一些化合物在 HDAC 抑制试验中显示出低于 100 nM 的活性,在针对三种肿瘤细胞系的试验中具有亚微摩尔的 IC50 值,并且在人和小鼠微粒体中观察到显著的稳定性。选择了三个代表性的化合物进行进一步的表征,并提交了针对一系列 I 类和 II 类 HDAC 的选择性概况以及初步的体内药代动力学(PK)实验。尽管它们在微粒体中的稳定性很高,但这些化合物在体内 PK 研究以及大鼠和人肝细胞中的清除率较高,表明主要的代谢途径是由非微粒体酶催化的。